This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Company partnered with Genomatica to produce cannabinoids through fermentation.
Creo, an ingredient company with a proprietary platform for producing natural rare cannabinoids without the cannabis plant, announced it has produced cannabigerol (CBG) and cannabigerolic acid (CBGA) through fermentation at 12,500-liter scale, with performance matching or exceeding expectations.
Rare cannabinoids such as CBG and CBGA are being studied for a range of potential benefits, but they're only found in small quantities in the plant and can be challenging to extract, making CBGA hard to produce at scale.